HBIO

Harvard Bioscience, Inc.

$9.26

1.87%
SectorHealthcareIndustryMedical Instruments & SuppliesCountryUnited States

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.

Source: Yahoo Finance
AI summary

Price & performance

1M+4.9%
3M+39.4%
YTD+28.5%
1Y+108.8%
52-week range—
Beta1.98
Full chart and returns against a benchmark

Q-Score

35/ 100

Quality against peers; 50 is the peer median.

Growth37
Risk36
Performance37
Valuation44
Profitability53
Leverage28
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$86.6M-8.1%
Net income-$56.7M
Net margin-65.5%-52.3 pts
Historical fundamentals

Revenue exposure

55%of revenue from outside the US
United States45%
EMEA31%
China13%
Regions, segments, customers and suppliers

Valuation

HBIOIndustryP/E—49.36P/S0.483.73EV/EBITDA46.7923.12P/B5.683.92PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 10next report, before the open
EPS estimate$-0.17
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate